STAT signaling in mammary gland differentiation, cell survival and tumorigenesis

Molecular and Cellular Endocrinology

Volumn 382, Issue 1, 2014, Pages 560-569

  Haricharan, S ^a   Li, Y ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Involution; Lactation; Mammary gland development; Pregnancy; STATs

Indexed keywords

STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN;

APOPTOSIS; ARTICLE; BREAST CELL; BREAST DEVELOPMENT; BREAST TUMOR; CANCER RISK; CARCINOGENESIS; CELL DEATH; CELL SURVIVAL; DEVELOPMENTAL STAGE; DISEASE MARKER; HUMAN; INVOLUTION; MILK; MILK PRODUCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; SIGNAL TRANSDUCTION; STROMA; TISSUE DIFFERENTIATION;

BREAST CANCER; INVOLUTION; LACTATION; MAMMARY GLAND DEVELOPMENT; PREGNANCY; STATS;

ANIMALS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL SURVIVAL; FEMALE; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY GLANDS, HUMAN; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84888306068     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.03.014     Document Type: Article

References (127)

1. Abell K., Bilancio A., Clarkson R.W., Tiffen P.G., Altaparmakov A.I., Burdon T.G., Asano T., Vanhaesebroeck B., Watson C.J. Stat3-induced apoptosis requires a molecular switch in PI(3)K subunit composition. Nat. Cell. Biol. 2005, 7:392-398.
2. Akira S. Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells 1999, 17:138-146.
3. Albrektsen G., Heuch I., Thoresen S., Kvale G. Family history of breast cancer and short-term effects of childbirths on breast cancer risk. Int. J. Cancer 2006, 119:1468-1474.
4. Barbieri I., Pensa S., Pannellini T., Quaglino E., Maritano D., Demaria M., Voster A., Turkson J., Cavallo F., Watson C.J., et al. Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res. 2010, 70:2558-2567.
5. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., Guldberg P., Sehested M., Nesland J.M., Lukas C., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
6. Bednorz N.L., Brill B., Klein A., Gabel K., Groner B. Tracking the activation of Stat5 through the expression of an inducible reporter gene in a transgenic mouse line. Endocrinology 2011, 152:1935-1947.
7. Bertucci P.Y., Quaglino A., Pozzi A.G., Kordon E.C., Pecci A. Glucocorticoid-induced impairment of mammary gland involution is associated with STAT5 and STAT3 signaling modulation. Endocrinology 2010, 151:5730-5740.
8. Blakely C.M., Sintasath L., D'Cruz C.M., Hahn K.T., Dugan K.D., Belka G.K., Chodosh L.A. Developmental stage determines the effects of MYC in the mammary epithelium. Development 2005, 132:1147-1160.
9. Bogorad R.L., Courtillot C., Mestayer C., Bernichtein S., Harutyunyan L., Jomain J.B., Bachelot A., Kuttenn F., Kelly P.A., Goffin V., Touraine P. Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc. Natl. Acad. Sci. USA 2008, 105:14533-14538.
10. Borges V.F., Schedin P.J. Pregnancy-associated breast cancer: an entity needing refinement of the definition. Cancer 2012, 118:3226-3228.
11. Boulanger C.A., Wagner K.U., Smith G.H. Parity-induced mouse mammary epithelial cells are pluripotent, self-renewing and sensitive to TGF-beta1 expression. Oncogene 2005, 24:552-560.
12. Braunstein J., Brutsaert S., Olson R., Schindler C. STATs dimerize in the absence of phosphorylation. J. Biol. Chem. 2003, 278:34133-34140.
13. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., Darnell J.E. Stat3 as an oncogene. Cell 1999, 98:295-303.
14. Bromberg J. Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development. Breast Cancer Res. 2000, 2:86-90.
15. Caffarel M.M., Zaragoza R., Pensa S., Li J., Green A.R., Watson C.J. Constitutive activation of JAK2 in mammary epithelium elevates Stat5 signalling, promotes alveologenesis and resistance to cell death, and contributes to tumourigenesis. Cell. Death Differ. 2012, 19:511-522.
16. Cerliani J.P., Guillardoy T., Giulianelli S., Vaque J.P., Gutkind J.S., Vanzulli S.I., Martins R., Zeitlin E., Lamb C.A., Lanari C. Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer. Cancer Res. 2011, 71:3720-3731.
17. Chan C.B., Liu X., Ensslin M.A., Dillehay D.L., Ormandy C.J., Sohn P., Serra R., Ye K. PIKE-A is required for prolactin-mediated STAT5a activation in mammary gland development. EMBO J. 2010, 29:956-968.
18. Chan S.R., Vermi W., Luo J., Lucini L., Rickert C., Fowler A.M., Lonardi S., Arthur C., Young L.J., Levy D.E., et al. STAT1-deficient mice spontaneously develop estrogen receptor alpha-positive luminal mammary carcinomas. Breast Cancer Res.: BCR 2012, 14:R16.
19. Chapman R.S., Lourenco P.C., Tonner E., Flint D.J., Selbert S., Takeda K., Akira S., Clarke A.R., Watson C.J. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev. 1999, 13:2604-2616.
20. Charpin C., Secq V., Giusiano S., Carpentier S., Andrac L., Lavaut M.N., Allasia C., Bonnier P., Garcia S. A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int. J. Cancer 2009, 124:2124-2134.
21. Chen X., Vinkemeier U., Zhao Y., Jeruzalmi D., Darnell J.E., Kuriyan J. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 1998, 93:827-839.
22. Chen C.C., Stairs D.B., Boxer R.B., Belka G.K., Horseman N.D., Alvarez J.V., Chodosh L.A. Autocrine prolactin induced by the Pten-Akt pathway is required for lactation initiation and provides a direct link between the Akt and Stat5 pathways. Genes Dev. 2012, 26:2154-2168.
23. Choi Y.S., Chakrabarti R., Escamilla-Hernandez R., Sinha S. Elf5 conditional knockout mice reveal its role as a master regulator in mammary alveolar development: failure of Stat5 activation and functional differentiation in the absence of Elf5. Dev. Biol. 2009, 329:227-241.
24. Clarkson R.W., Wayland M.T., Lee J., Freeman T., Watson C.J. Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in post-lactational regression. Breast Cancer Res.: BCR 2004, 6:R92-R109.
25. Clarkson R.W., Boland M.P., Kritikou E.A., Lee J.M., Freeman T.C., Tiffen P.G., Watson C.J. The genes induced by signal transducer and activators of transcription (STAT)3 and STAT5 in mammary epithelial cells define the roles of these STATs in mammary development. Mol. Endocrinol. 2006, 20:675-685.
26. Cobanoglu O., Zaitoun I., Chang Y.M., Shook G.E., Khatib H. Effects of the signal transducer and activator of transcription 1 (STAT1) gene on milk production traits in Holstein dairy cattle. J. Dairy Sci. 2006, 89:4433-4437.
27. Cotarla I., Ren S., Zhang Y., Gehan E., Singh B., Furth P.A. Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int. J. Cancer 2004, 108:665-671.
28. Courtillot C., Chakhtoura Z., Bogorad R., Genestie C., Bernichtein S., Badachi Y., Janaud G., Akakpo J.P., Bachelot A., Kuttenn F., et al. Characterization of two constitutively active prolactin receptor variants in a cohort of 95 women with multiple breast fibroadenomas. J. Clin. Endocrinol. Metab. 2010, 95:271-279.
29. Creamer B.A., Sakamoto K., Schmidt J.W., Triplett A.A., Moriggl R., Wagner K.U. Stat5 promotes survival of mammary epithelial cells through transcriptional activation of a distinct promoter in Akt1. Mol. Cell. Biol. 2010, 30:2957-2970.
30. Cui Y., Riedlinger G., Miyoshi K., Tang W., Li C., Deng C.X., Robinson G.W., Hennighausen L. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol. Cell. Biol. 2004, 24:8037-8047.
31. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
32. Darnell J.E. Reflections on STAT3, STAT5, and STAT6 as fat STATs. Proc. Natl. Acad. Sci. USA 1996, 93:6221-6224.
33. Darnell J.E. STATs and gene regulation. Science 1997, 277:1630-1635.
34. DeNardo D.G., Barreto J.B., Andreu P., Vasquez L., Tawfik D., Kolhatkar N., Coussens L.M. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009, 16:91-102.
35. Desmedt C., Haibe-Kains B., Wirapati P., Buyse M., Larsimont D., Bontempi G., Delorenzi M., Piccart M., Sotiriou C. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res.: Official J. Am. Assoc. Cancer Res. 2008, 14:5158-5165.
36. Diaz N., Minton S., Cox C., Bowman T., Gritsko T., Garcia R., Eweis I., Wloch M., Livingston S., Seijo E., et al. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin. Cancer Res.: Official J. Am. Assoc. Cancer Res. 2006, 12:20-28.
37. Dong J., Tong T., Reynado A.M., Rosen J.M., Huang S., Li Y. Genetic manipulation of individual somatic mammary cells in vivo reveals a master role of STAT5a in inducing alveolar fate commitment and lactogenesis even in the absence of ovarian hormones. Dev. Biol. 2010, 346:196-203.
38. Durbin J.E., Hackenmiller R., Simon M.C., Levy D.E. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996, 84:443-450.
39. Faulds M.H., Pettersson K., Gustafsson J.A., Haldosen L.A. Cross-talk between ERs and signal transducer and activator of transcription 5 is E2 dependent and involves two functionally separate mechanisms. Mol. Endocrinol. 2001, 15:1929-1940.
40. Gallego M.I., Binart N., Robinson G.W., Okagaki R., Coschigano K.T., Perry J., Kopchick J.J., Oka T., Kelly P.A., Hennighausen L. Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects. Dev. Biol. 2001, 229:163-175.
41. Goffin V., Bogorad R.L., Touraine P. Identification of gain-of-function variants of the human prolactin receptor. Methods Enzymol. 2010, 484:329-355.
42. Hakim O., Sung M.H., Nakayamada S., Voss T., Baek S., Hager G. Spatial congregation of STAT binding directs selective nuclear architecture during T cell functional differentiation. Genome Res. 2012.
43. Harris J., Stanford P.M., Sutherland K., Oakes S.R., Naylor M.J., Robertson F.G., Blazek K.D., Kazlauskas M., Hilton H.N., Wittlin S., et al. Socs2 and elf5 mediate prolactin-induced mammary gland development. Mol. Endocrinol. 2006, 20:1177-1187.
44. Heim M.H., Kerr I.M., Stark G.R., Darnell J.E. Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway. Science 1995, 267:1347-1349.
45. Henry M.D., Triplett A.A., Oh K.B., Smith G.H., Wagner K.U. Parity-induced mammary epithelial cells facilitate tumorigenesis in MMTV-neu transgenic mice. Oncogene 2004, 23:6980-6985.
46. Horvath C.M., Wen Z., Darnell J.E. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev. 1995, 9:984-994.
47. Hughes K., Wickenden J.A., Allen J.E., Watson C.J. Conditional deletion of Stat3 in mammary epithelium impairs the acute phase response and modulates immune cell numbers during post-lactational regression. J. Pathol. 2012, 227:106-117.
48. Humphreys R.C., Bierie B., Zhao L., Raz R., Levy D., Hennighausen L. Deletion of Stat3 blocks mammary gland involution and extends functional competence of the secretory epithelium in the absence of lactogenic stimuli. Endocrinology 2002, 143:3641-3650.
49. Iavnilovitch E., Cardiff R.D., Groner B., Barash I. Deregulation of Stat5 expression and activation causes mammary tumors in transgenic mice. Int. J. Cancer 2004, 112:607-619.
50. Iliopoulos D., Jaeger S.A., Hirsch H.A., Bulyk M.L., Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol. Cell 2010, 39:493-506.
51. Jahchan N.S., Wang D., Bissell M.J., Luo K. SnoN regulates mammary gland alveologenesis and onset of lactation by promoting prolactin/Stat5 signaling. Development 2012, 139:3147-3156.
52. Jensen S.M., Meijer S.L., Kurt R.A., Urba W.J., Hu H.M., Fox B.A. Regression of a mammary adenocarcinoma in STAT6-/- mice is dependent on the presence of STAT6-reactive T cells. J. Immunol. 2003, 170:2014-2021.
53. Kaplan M.H., Schindler U., Smiley S.T., Grusby M.J. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996, 4:313-319.
54. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., Schreiber R.D. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 1998, 95:7556-7561.
55. Ke Y., Lesperance J., Zhang E.E., Bard-Chapeau E.A., Oshima R.G., Muller W.J., Feng G.S. Conditional deletion of Shp2 in the mammary gland leads to impaired lobular-alveolar outgrowth and attenuated Stat5 activation. J. Biol. Chem. 2006, 281:34374-34380.
56. Khaled W.T., Read E.K., Nicholson S.E., Baxter F.O., Brennan A.J., Came P.J., Sprigg N., McKenzie A.N., Watson C.J. The IL-4/IL-13/Stat6 signalling pathway promotes luminal mammary epithelial cell development. Development 2007, 134:2739-2750.
57. Khodarev N., Ahmad R., Rajabi H., Pitroda S., Kufe T., McClary C., Joshi M.D., MacDermed D., Weichselbaum R., Kufe D. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene 2010, 29:920-929.
58. Khodarev N.N., Roizman B., Weichselbaum R.R. Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth. Clin. Cancer Res.: Official J. Am. Assoc. Cancer Res. 2012, 18:3015-3021.
59. Kim T.K., Maniatis T. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science 1996, 273:1717-1719.
60. Klover P.J., Muller W.J., Robinson G.W., Pfeiffer R.M., Yamaji D., Hennighausen L. Loss of STAT1 from mouse mammary epithelium results in an increased neu-induced tumor burden. Neoplasia 2010, 12:899-905.
61. Kreuzaler P.A., Staniszewska A.D., Li W., Omidvar N., Kedjouar B., Turkson J., Poli V., Flavell R.A., Clarkson R.W., Watson C.J. Stat3 controls lysosomal-mediated cell death in vivo. Nat. Cell Biol. 2011, 13:303-309.
62. Kritikou E.A., Sharkey A., Abell K., Came P.J., Anderson E., Clarkson R.W., Watson C.J. A dual, non-redundant, role for LIF as a regulator of development and STAT3-mediated cell death in mammary gland. Development 2003, 130:3459-3468.
63. Li X., Leung S., Qureshi S., Darnell J.E., Stark G.R. Formation of STAT1-STAT2 heterodimers and their role in the activation of IRF-1 gene transcription by interferon-alpha. J. Biol. Chem. 1996, 271:5790-5794.
64. Li M., Liu X., Robinson G., Bar-Peled U., Wagner K.U., Young W.S., Hennighausen L., Furth P.A. Mammary-derived signals activate programmed cell death during the first stage of mammary gland involution. Proc. Natl. Acad. Sci. USA 1997, 94:3425-3430.
65. Li Y., Kumar K.G., Tang W., Spiegelman V.S., Fuchs S.Y. Negative regulation of prolactin receptor stability and signaling mediated by SCF(beta-TrCP) E3 ubiquitin ligase. Mol. Cell. Biol. 2004, 24:4038-4048.
66. Liao D., Luo Y., Markowitz D., Xiang R., Reisfeld R.A. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 2009, 4:e7965.
67. Lim E.J., Joung Y.H., Jung S.M., Park S.H., Park J.H., Kim S.Y., Hwang T.S., Hong D.Y., Chung S.C., Ye S.K., et al. Hemin inhibits cyclin D1 and IGF-1 expression via STAT5b under hypoxia in ERalpha-negative MDA-MB 231 breast cancer cells. Int. J. Oncol. 2010, 36:1243-1251.
68. Lindeman G.J., Wittlin S., Lada H., Naylor M.J., Santamaria M., Zhang J.G., Starr R., Hilton D.J., Alexander W.S., Ormandy C.J., Visvader J. SOCS1 deficiency results in accelerated mammary gland development and rescues lactation in prolactin receptor-deficient mice. Genes Dev. 2001, 15:1631-1636.
69. Liu X., Robinson G.W., Hennighausen L. Activation of Stat5a and Stat5b by tyrosine phosphorylation is tightly linked to mammary gland differentiation. Mol. Endocrinol. 1996, 10:1496-1506.
70. Liu X., Robinson G.W., Wagner K.U., Garrett L., Wynshaw-Boris A., Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 1997, 11:179-186.
71. Liu A., Liu Y., Jin Z., Hu Q., Lin L., Jou D., Yang J., Xu Z., Wang H., Li C., Lin J. XZH-5 inhibits STAT3 phosphorylation and enhances the cytotoxicity of chemotherapeutic drugs in human breast and pancreatic cancer cells. PLoS One 2012, 7:e46624.
72. Long W., Wagner K.U., Lloyd K.C., Binart N., Shillingford J.M., Hennighausen L., Jones F.E. Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5. Development 2003, 130:5257-5268.
73. MacMahon B., Cole P., Lin T.M., Lowe C.R., Mirra A.P., Ravnihar B., Salber E.J., Valaoras V.G., Yuasa S. Age at first birth and breast cancer risk. Bull. World Health Organ. 1970, 43:209-221.
74. Magkou C., Giannopoulou I., Theohari I., Fytou A., Rafailidis P., Nomikos A., Papadimitriou C., Nakopoulou L. Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer. Histopathology 2012, 60:1125-1132.
75. Matulka L.A., Triplett A.A., Wagner K.U. Parity-induced mammary epithelial cells are multipotent and express cell surface markers associated with stem cells. Dev. Biol. 2007, 303:29-44.
76. Meraz M.A., White J.M., Sheehan K.C., Bach E.A., Rodig S.J., Dighe A.S., Kaplan D.H., Riley J.K., Greenlund A.C., Campbell D., et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996, 84:431-442.
77. Meyer T., Marg A., Lemke P., Wiesner B., Vinkemeier U. DNA binding controls inactivation and nuclear accumulation of the transcription factor Stat1. Genes Dev. 2003, 17:1992-2005.
78. Milani E.S., Brinkhaus H., Dueggeli R., Klebba I., Mueller U., Stadler M., Kohler H., Smalley M.J., Bentires-Alj M. Protein tyrosine phosphatase 1B restrains mammary alveologenesis and secretory differentiation. Development 2012.
79. Nevalainen M.T., Xie J., Torhorst J., Bubendorf L., Haas P., Kononen J., Sauter G., Rui H. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J. Clin. Oncol. 2004, 22:2053-2060.
80. Norton J.A., Li M., Lee N.C., Tsung K. Inhibition of host signal transducer and activator of transcription factor 6 results in cure with cyclophosphamide and interleukin 12 immunotherapy. Ann. Surg. Oncol. 2006, 13:118-124.
81. Oliver C.H., Khaled W.T., Frend H., Nichols J., Watson C.J. The Stat6-regulated KRAB domain zinc finger protein Zfp157 regulates the balance of lineages in mammary glands and compensates for loss of Gata-3. Genes Dev. 2012, 26:1086-1097.
82. Ostrand-Rosenberg S., Grusby M.J., Clements V.K. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J. Immunol. 2000, 165:6015-6019.
83. Ostrand-Rosenberg S., Clements V.K., Terabe M., Park J.M., Berzofsky J.A., Dissanayake S.K. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent. J. Immunol. 2002, 169:5796-5804.
84. Park C., Li S., Cha E., Schindler C. Immune response in Stat2 knockout mice. Immunity 2000, 13:795-804.
85. Peck A.R., Witkiewicz A.K., Liu C., Stringer G.A., Klimowicz A.C., Pequignot E., Freydin B., Tran T.H., Yang N., Rosenberg A.L., et al. Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J. Clin. Oncol. 2011, 29:2448-2458.
86. Philp J.A., Burdon T.G., Watson C.J. Differential activation of STATs 3 and 5 during mammary gland development. FEBS Lett. 1996, 396:77-80.
87. Pranada A.L., Metz S., Herrmann A., Heinrich P.C., Muller-Newen G. Real time analysis of STAT3 nucleocytoplasmic shuttling. J. Biol. Chem. 2004, 279:15114-15123.
88. Quarrie L.H., Addey C.V., Wilde C.J. Programmed cell death during mammary tissue involution induced by weaning, litter removal, and milk stasis. J. Cell Physiol. 1996, 168:559-569.
89. Raven J.F., Williams V., Wang S., Tremblay M.L., Muller W.J., Durbin J.E., Koromilas A.E. Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. Cell Cycle 2011, 10:794-804.
90. Reddy J.P., Peddibhotla S., Bu W., Zhao J., Haricharan S., Du Y.C., Podsypanina K., Rosen J.M., Donehower L.A., Li Y. Defining the ATM-mediated barrier to tumorigenesis in somatic mammary cells following ErbB2 activation. Proc. Natl. Acad. Sci. USA 2010, 107:3728-3733.
91. Sahni M., Ambrosetti D.C., Mansukhani A., Gertner R., Levy D., Basilico C. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. 1999, 13:1361-1366.
92. Sakamoto K., Creamer B.A., Triplett A.A., Wagner K.U. The Janus kinase 2 is required for expression and nuclear accumulation of cyclin D1 in proliferating mammary epithelial cells. Mol. Endocrinol. 2007, 21:1877-1892.
93. Sakamoto K., Triplett A.A., Schuler L.A., Wagner K.U. Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer. Oncogene 2010, 29:5359-5369.
94. Santos S.J., Haslam S.Z., Conrad S.E. Signal transducer and activator of transcription 5a mediates mammary ductal branching and proliferation in the nulliparous mouse. Endocrinology 2010, 151:2876-2885.
95. Schere-Levy C., Buggiano V., Quaglino A., Gattelli A., Cirio M.C., Piazzon I., Vanzulli S., Kordon E.C. Leukemia inhibitory factor induces apoptosis of the mammary epithelial cells and participates in mouse mammary gland involution. Exp. Cell Res. 2003, 282:35-47.
96. Shillingford J.M., Miyoshi K., Robinson G.W., Grimm S.L., Rosen J.M., Neubauer H., Pfeffer K., Hennighausen L. Jak2 is an essential tyrosine kinase involved in pregnancy-mediated development of mammary secretory epithelium. Mol. Endocrinol. 2002, 16:563-570.
97. Shimoda K., van Deursen J., Sangster M.Y., Sarawar S.R., Carson R.T., Tripp R.A., Chu C., Quelle F.W., Nosaka T., Vignali D.A., et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996, 380:630-633.
98. Socolovsky M., Fallon A.E., Wang S., Brugnara C., Lodish H.F. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1999, 98:181-191.
99. Sotgia F., Schubert W., Pestell R.G., Lisanti M.P. Genetic ablation of caveolin-1 in mammary epithelial cells increases milk production and hyper-activates STAT5a signaling. Cancer Biol. Ther. 2006, 5:292-297.
100. Takeda K., Tanaka T., Shi W., Matsumoto M., Minami M., Kashiwamura S., Nakanishi K., Yoshida N., Kishimoto T., Akira S. Essential role of Stat6 in IL-4 signalling. Nature 1996, 380:627-630.
101. Takeda K., Kaisho T., Yoshida N., Takeda J., Kishimoto T., Akira S. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J. Immunol. 1998, 161:4652-4660.
102. Teglund S., McKay C., Schuetz E., van Deursen J.M., Stravopodis D., Wang D., Brown M., Bodner S., Grosveld G., Ihle J.N. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998, 93:841-850.
103. Thierfelder W.E., van Deursen J.M., Yamamoto K., Tripp R.A., Sarawar S.R., Carson R.T., Sangster M.Y., Vignali D.A., Doherty P.C., Grosveld G.C., Ihle J.N. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 1996, 382:171-174.
104. Tiffen P.G., Omidvar N., Marquez-Almuina N., Croston D., Watson C.J., Clarkson R.W. A dual role for Oncostatin M signaling in the differentiation and death of mammary epithelial cells in vivo. Mol. Endocrinol. 2008, 22:2677-2688.
105. Tran T.H., Utama F.E., Lin J., Yang N., Sjolund A.B., Ryder A., Johnson K.J., Neilson L.M., Liu C., Brill K.L., et al. Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism. Cancer Res. 2010, 70:1711-1721.
106. Tsuyada A., Chow A., Wu J., Somlo G., Chu P., Loera S., Luu T., Li A.X., Wu X., Ye W., et al. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res. 2012, 72:2768-2779.
107. Turkoz F.P., Solak M., Petekkaya I., Keskin O., Kertmen N., Sarici F., Arik Z., Babacan T., Ozisik Y., Altundag K. Association between common risk factors and molecular subtypes in breast cancer patients. Breast 2012.
108. Vafaizadeh V., Klemmt P., Brendel C., Weber K., Doebele C., Britt K., Grez M., Fehse B., Desrivieres S., Groner B. Mammary epithelial reconstitution with gene-modified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation. Stem Cells 2010, 28:928-938.
109. Vafaizadeh V., Klemmt P.A., Groner B. Stat5 assumes distinct functions in mammary gland development and mammary tumor formation. Front Biosci. 2012, 17:1232-1250.
110. Wagner K.U., Boulanger C.A., Henry M.D., Sgagias M., Hennighausen L., Smith G.H. An adjunct mammary epithelial cell population in parous females: its role in functional adaptation and tissue renewal. Development 2002, 129:1377-1386.
111. Wagner K.U., Krempler A., Triplett A.A., Qi Y., George N.M., Zhu J., Rui H. Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Mol. Cell. Biol. 2004, 24:5510-5520.
112. Wang Y., Cheng C.H. ERalpha and STAT5a cross-talk: interaction through C-terminal portions of the proteins decreases STAT5a phosphorylation, nuclear translocation and DNA-binding. FEBS Lett. 2004, 572:238-244.
113. Watson C.J., Miller W.R. Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br. J. Cancer 1995, 71:840-844.
114. Watson C.J. Stat transcription factors in mammary gland development and tumorigenesis. J. Mammary Gland Biol. Neoplasia 2001, 6:115-127.
115. Weichselbaum R.R., Ishwaran H., Yoon T., Nuyten D.S., Baker S.W., Khodarev N., Su A.W., Shaikh A.Y., Roach P., Kreike B., et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl. Acad. Sci. USA 2008, 105:18490-18495.
116. Widschwendter A., Tonko-Geymayer S., Welte T., Daxenbichler G., Marth C., Doppler W. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin. Cancer Res.: Official J. Am. Assoc. Cancer Res. 2002, 8:3065-3074.
117. Xu M., Nie L., Kim S.H., Sun X.H. STAT5-induced Id-1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPbeta. EMBO J. 2003, 22:893-904.
118. Xu J., Zhang Y., Berry P.A., Jiang J., Lobie P.E., Langenheim J.F., Chen W.Y., Frank S.J. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex. Mol. Endocrinol. 2011, 25:597-610.
119. Yamaji D., Na R., Feuermann Y., Pechhold S., Chen W., Robinson G.W., Hennighausen L. Development of mammary luminal progenitor cells is controlled by the transcription factor STAT5A. Genes Dev. 2009, 23:2382-2387.
120. Yamaji D., Kang K., Robinson G.W., Hennighausen L. Sequential activation of genetic programs in mouse mammary epithelium during pregnancy depends on STAT5A/B concentration. Nucleic Acids Res. 2012.
121. Yamashita H., Nishio M., Ando Y., Zhang Z., Hamaguchi M., Mita K., Kobayashi S., Fujii Y., Iwase H. Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocrine-Relat. Cancer 2006, 13:885-893.
122. Yan M., Jene N., Byrne D., Millar E.K., O'Toole S.A., McNeil C.M., Bates G.J., Harris A.L., Banham A.H., Sutherland R.L., Fox S.B. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res.: BCR 2011, 13:R47.
123. Yang J., Liao D., Chen C., Liu Y., Chuang T.H., Xiang R., Markowitz D., Reisfeld R.A., Luo Y. Tumor associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. Stem Cells 2012.
124. Yoshimoto G., Miyamoto T., Jabbarzadeh-Tabrizi S., Iino T., Rocnik J.L., Kikushige Y., Mori Y., Shima T., Iwasaki H., Takenaka K., et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 2009, 114:5034-5043.
125. Zhang X., Yue P., Page B.D., Li T., Zhao W., Namanja A.T., Paladino D., Zhao J., Chen Y., Gunning P.T., Turkson J. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc. Natl. Acad. Sci. USA 2012, 109:9623-9628.
126. Zhao L., Hart S., Cheng J., Melenhorst J.J., Bierie B., Ernst M., Stewart C., Schaper F., Heinrich P.C., Ullrich A., et al. Mammary gland remodeling depends on gp130 signaling through Stat3 and MAPK. J. Biol. Chem. 2004, 279:44093-44100.
127. Zhou J., Bi C., Janakakumara J.V., Liu S.C., Chng W.J., Tay K.G., Poon L.F., Xie Z., Palaniyandi S., Yu H., et al. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 2009, 113:4052-4062.